sign in sign up
<<
Home , Adaptive immune system

Glossary of terms

• 1L, 2L, 3L: first, second and third line of treatment • FL: Follicular Lymphoma • ADC: -Drug-Conjugate • FDA: Food and Drug Administration (US) • AML: Acute Myeloid Leukemia • FDG PET/CT: Positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro- D- glucose integrated with computed tomography • ARC: Antibody-Radionuclide-Conjugate • GMP: Good Manufacturing Practice • APAC: Asia-Pacific • Haem-Oncs: medical oncology, haematology, onco-haematology specialists • (A)SCT: (Autologous) stem cell transplant • HCP: Healthcare Professional • ASH: American Society of Hematology Annual Meeting • HH1: Betalutin® consists of the radionuclide lutetium-177 which is joined to the B-cell • B-cell: A type of (white cell) in the humoral of seeking antibody HH1. The HH1 antibody in Betalutin® binds to the CD37 B-cells the body’s adaptive . Can be distinguished from other (NHL cells). by the presence of a on the B-cell’s outer surface known as a receptor (BCR). This specialized receptor protein allows a • IND: Investigational New Drug B-cell to bind to a specific antigen. • KI: Kinase Inhibitor • CD20: B-lymphocyte antigen CD20 is an activated-glycosylated • KOL: Key Opinion Leader phosphoprotein expressed in the surface of all B-cells beginning at the pro-B phase and progressively increasing in concentration until maturity • LCM: Life-cycle management • CD37: B-lymphocyte antigen CD-37 is a protein, a member of the • Lu-177: Radionuclide lutetium-177 transmembrane 4 superfamily, also known as the tetraspanin superfamily of • MoA: Mechanism of Action cell surface • MBq: Megabecquerel (radioactivity measurement unit) • chHH1: chimeric version of the HH1 antibody • MCL: Mantle Cell Lymphoma • CLL: Chronic Lymphocytic Leukemia • M.D: Medical Doctor • CR: Complete Response • NDA: New Drug Application • DLBCL: Diffuse Large B-Cell Lymphoma • NHL: Non-Hodgkin Lymphoma • DOR: Duration of Response • ODD: Orphan Drug Designation • EANM: European Association of Nuclear Medicine • ORR: Overall Response Rate (CR plus PR) • EMEA: Europe, Middle East, and Africa 1 Glossary of terms, cont.

• OS: Overall Survival • PARADIGME: name of Nordic Nanovector’s pivotal Phase 2 study • PD: Progressive Disease • PFS: Progression Free Survival • PR: Partial Response • PSI: Paul Scherrer Institute • QoL: Quality of Life • R: Rituximab • R-Benda/R-B/RB: Rituximab, bendamustine • R-Chemo: combination treatment consisting of rituximab plus one (i.e., bendamustine, fludarabine) or more (i.e., CHOP, CVP) chemotherapy agents • R-CHOP: Rituximab, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), prednisolone • R-CVP: Rituximab, cyclophosphamide, vincristine, prednisone • R-Squared: combination treatment consisting of rituximab plus lenalidomide • RIT: Radioimmunotherapy • SAB: Scientific Advisory Board • SD: Stable Disease • SPECT/CT: single photon emission computed tomography (SPECT) integrated with computed tomography (CT) • T-cell: A type of lymphocyte () that plays a central role in cell-mediated immunity. Can be distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on the cell surface. They are called T-cells because they mature in the • TKI: Tyrosine Kinase Inhibitor • TPP: Target Product Profile • TTR: Time to Recurrence 2